Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Company release
Herantis Pharma Plc, Major shareholder announcements, 3 March 2026 at 17:20 EET
Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Herantis Pharma Plc ("Herantis") has, on 3 March 2026, received a notification from EIC Fund SA, SICAV-RAIF in accordance with chapter 9, section 10 of the Securities Market Act. According to the notification, holdings of EIC Fund SA, SICAV-RAIF in Herantis have exceeded the level of 10 per cent, as a result of share transactions concluded on 2 March 2026.
Herantis has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date of the notification received by Herantis.
| Total positions of EIC Fund SA, SICAV-RAIF subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 11.15 | 11.15 | 26,503,817 | |
| Position of previous notification (if applicable) | ||||
| Notified details of the resulting situation on the date on which the threshold was crossed or reached: | ||||
| A: Shares and voting rights | ||||
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI4000087861 | 2,954,221 | 11.15 | ||
| SUBTOTAL A | 2,954,221 | 11.15 | ||
| Information in relation to the person subject to the notification obligation: | |||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | |||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| European Investment Bank | |||
| EIC Fund | 11.15 | 11.15 | |
| Additional information: |
Shareholder (EIC Fund) is an alternative investment fund (SICAV-RAIF) established by the European Commission. The sole shareholder of EIC Fund is the European Investment Bank (EIB). The portfolio management of EIC Fund, including the exercise of control of the shares and voting rights in the (underlying) issuer, has been assumed by Alter Domus Management Company S.A. as the appointed alternative investment fund manager of the EIC Fund. EIC Fund’s ownership is a result of the share issue completed on 5 December 2023 (5.31 % of shares and votes in the issuer), share issue completed on 6 February 2025 (9.89 % of shares and votes in the issuer) and the share issue completed on 11 February 2026 (11.15 % of shares and votes in the issuer). |
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease. The Company's lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson's disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson's patients.
Herantis is listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com